WHO plans to evaluate raw materials prompt industry cost worries
This article was originally published in SRA
Executive Summary
The World Health Organization is starting a pilot under which it will prequalify active pharmaceutical ingredients for products treating three infectious diseases (HIV/AIDS, malaria and tuberculosis), because the globalisation of drug production has made it difficult to verify their quality, it says1. However, the pharmaceutical industry is concerned the pilot may increase company costs while a US think tank is worried it may take away from the WHO's core business.